Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Pierluigi Porcu"'
Autor:
Sushil Ghimire, Joanne Filicko-O'Hara, S. Onder Alpdogan, John L. Wagner, Matthew Carabasi, Sameh Gaballa, Michael Ramirez, Mark Weiss, Andrew E. Chapman, Jerald Z. Gong, Pierluigi Porcu, Jonathan Pan, Barbara Pro, Lewis J. Rose, Martina DiMeglio, Ubaldo E. Martinez-Outschoorn, Neal Flomenberg
Publikováno v:
Leukemia & Lymphoma. 62:590-597
We developed an outpatient salvage chemotherapy regimen using bendamustine, ofatumumab, carboplatin and etoposide (BOCE) to treat relapsed/refractory non-Hodgkin lymphoma (RR NHL) in a single-center phase I/II study. Primary objectives were safety, t
Autor:
Pamela Heeter, Erika Cavallone, Frank McCormick, Lawrence K. Kaplan, Laura B. Pincus, Wade Berry, Basem M. William, Aaron Zhan, Khoan Vu, Jonathan E. Brammer, Chen-Yen Yang, Charalambos Andreadis, Matthew J. Wieduwilt, Pierluigi Porcu, Weiyun Z. Ai, Chi-Heng Wu
Publikováno v:
Clinical Cancer Research. 26:1000-1008
Purpose: The histone deacetylase (HDAC) inhibitor romidepsin and the anthracycline liposomal doxorubicin (LD) have modest single-agent activity in cutaneous T-cell lymphoma (CTCL) and peripheral T-cell lymphoma (PTCL). We investigated the safety and
Autor:
Kami J. Maddocks, Beth Christian, Amelia Langston, Mary Jo Lechowicz, Lai Wei, Steven M. Devine, Kristie A. Blum, Leonard T. Heffner, Christopher R. Flowers, Pierluigi Porcu, Jonathon B. Cohen
Publikováno v:
Cancer. 126:1235-1242
Background Both gemcitabine and bendamustine have been evaluated in patients with recurrent/refractory Hodgkin lymphoma but to the authors' knowledge not as a doublet. The authors completed a phase 1/2 trial to identify the optimal dose and frequency
Autor:
Stephen Couban, James R. Cook, Kevin Barton, Pierluigi Porcu, Louis S. Constine, Patrick J. Stiff, Stephen J. Forman, Glenn Mills, Thomas C. Shea, Richard I. Fisher, Douglas A. Stewart, John P. Leonard, Hongli Li, Jonathan W. Friedberg, Brad S. Kahl, Michael LeBlanc, Jane N. Winter, Sonali M. Smith, Zeina Al-Mansour, Lisa M. Rimsza, Deborah Marcellus
Publikováno v:
Leuk Lymphoma
Phase II data suggest a benefit to autotransplantation for aggressive T-NHL in first remission; randomized trials have yet to validate this. We performed a retrospective analysis of aggressive T-NHL patients in the intergroup randomized consolidative
Autor:
Ludmila Katherine Martin, Ying Huang, Robert A. Baiocchi, Shannon C. Kenney, Marisa F. Martin, Fengting Yan, Gerard J. Nuovo, Linda Villagomez, Richard F. Ambinder, Gerard Lozanski, Pierluigi Porcu, Bradley M. Haverkos, Joyce D. Fingeroth, Mark E. Lustberg, John T. Patton, Michael A. Caligiuri, Robert Cavaliere, James P Dugan
Publikováno v:
Clinical Cancer Research. 24:3273-3281
Purpose: Primary central nervous system posttransplant lymphoproliferative disorder (PCNS-PTLD) is a complication of solid organ transplantation with a poor prognosis and typically associated with Epstein–Barr virus (EBV). We hypothesized EBV lytic
Autor:
Adetokunbo, Oluwasanjo, Saritha, Kartan, William, Johnson, Onder, Alpdogan, Alejandro, Gru, Anjali, Mishra, Bradley M, Haverkos, Jerald, Gong, Pierluigi, Porcu
Publikováno v:
Cancer treatment and research. 176
Peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS) is a World Health Organization (WHO)-defined diagnostic category within the highly heterogeneous group of mature post-thymic T-cell neoplasms. It is the most common subtype of mature post
Autor:
Steven Horwitz, Owen A O'Connor, Barbara Pro, Tim Illidge, Michelle Fanale, Ranjana Advani, Nancy L Bartlett, Jacob Haaber Christensen, Franck Morschhauser, Eva Domingo-Domenech, Giuseppe Rossi, Won Seog Kim, Tatyana Feldman, Anne Lennard, David Belada, Árpád Illés, Kensei Tobinai, Kunihiro Tsukasaki, Su-Peng Yeh, Andrei Shustov, Andreas Hüttmann, Kerry J Savage, Sam Yuen, Swaminathan Iyer, Pier Luigi Zinzani, Zhaowei Hua, Meredith Little, Shangbang Rao, Joseph Woolery, Thomas Manley, Lorenz Trümper, David Aboulafia, Onder Alpdogan, Kiyoshi Ando, Luca Arcaini, Luca Baldini, Naresh Bellam, Nancy Bartlett, Dina Ben Yehuda, Fabio Benedetti, Peter Borchman, Dominique Bordessoule, Pauline Brice, Javier Briones, Dolores Caballero, Angelo Michele Carella, Hung Chang, June Weon Cheong, Seok-Goo Cho, Ilseung Choi, Sylvain Choquet, Andrei Colita, Angela Giovanna Congui, Francesco D'amore, Nam Dang, Kelly Davison, Sophie de Guibert, Peter de Nully Brown, Vincent Delwail, Judit Demeter, Francesco di Raimondo, Young Rok Do, Eva Domingo, Michael Douvas, Martin Dreyling, Thomas Ernst, Keith Fay, Silvia Fernandez Ferrero, Ian Winchester Flinn, Andres Forero-Torres, Christopher Fox, Jonathan Friedberg, Noriko Fukuhara, Jose Garcia-Marco, Jorge Gayoso Cruz, Jose Gomez Codina, Remy Gressin, Andrew Grigg, Ronit Gurion, Corinne Haioun, Roman Hajek, Mathias Hanel, Kiyohiko Hatake, Robert Hensen, Netanel Horowitz, Andreas Huttmann, Arpad Illes, Kenichi Ishizawa, Miguel Islas-Ohlmayer, Eric Jacobsen, Murali Janakiram, Wojciech Jurczak, Mark Kaminski, Koji Kato, Ilya Kirgner, Ching-Yuan Kuo, Mihaela Cornelia Lazaroiu, Katell Le Du, Jong-Seok Lee, Steven LeGouill, Paul LaRosee, Itai Levi, Brian Link, Herve Maisonneuve, Dai Maruyama, Jiri Mayer, John McCarty, Pam McKay, Yosuke Minami, Heidi Mocikova, Enrica Morra, Javier Munoz, Hirokazu Nagai, Owen O'Connor, Stephen Opat, Ruth Pettengell, Antonio Pezzutto, Michael Pfreundschuh, Andrzej Pluta, PierLuigi Porcu, Hang Quach, Alessandro Rambaldi, William Renwick, Ruben Reyes, Antonia Rodriguez Izquierdo, Jia Ruan, Chiara Rusconi, Gilles Salles, Armando Santoro, Jose Sarriera, Kerry Savage, Hirohiko Shibayama, Cheolwon Suh, Anna Sureda, Mitsune Tanimoto, Masafumi Taniwaki, Herve Tilly, Marek Trneny, Lorenz Trumper, Norifumi Tsukamoto, Umberto Vitolo, Jan Walewski, Eckhart Weidmann, Martin Wilhelm, Mathias Witzens-Harig, Abdulraheem Yacoub, Kazuhito Yamamoto, Sung-Soo Yoon, Hwan Jung Yun, Jasmine Zain
Publikováno v:
ECHELON-2 Study Group 2019, ' Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2) : a global, double-blind, randomised, phase 3 trial ', Lancet (London, England), vol. 393, no. 10168, pp. 229-240 . https://doi.org/10.1016/S0140-6736(18)32984-2
Horwitz, S, O'Connor, O A, Pro, B, Illidge, T, Fanale, M, Advani, R, Bartlett, N L, Christensen, J H, Morschhauser, F, Domingo-Domenech, E, Rossi, G, Kim, W S, Feldman, T, Lennard, A, Belada, D, Illés, Á, Tobinai, K, Tsukasaki, K, Yeh, S-P, Shustov, A, Hüttmann, A, Savage, K J, Yuen, S, Iyer, S, Zinzani, P L, Hua, Z, Little, M, Rao, S, Woolery, J, Manley, T, Trümper, L & ECHELON-2 Study Group 2019, ' Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2) : a global, double-blind, randomised, phase 3 trial ', Lancet, vol. 393, no. 10168, pp. 229-240 . https://doi.org/10.1016/S0140-6736(18)32984-2
Horwitz, S, O'Connor, O A, Pro, B, Illidge, T, Fanale, M, Advani, R, Bartlett, N L, Christensen, J H, Morschhauser, F, Domingo-Domenech, E, Rossi, G, Kim, W S, Feldman, T, Lennard, A, Belada, D, Illés, Á, Tobinai, K, Tsukasaki, K, Yeh, S-P, Shustov, A, Hüttmann, A, Savage, K J, Yuen, S, Iyer, S, Zinzani, P L, Hua, Z, Little, M, Rao, S, Woolery, J, Manley, T, Trümper, L & ECHELON-2 Study Group 2019, ' Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2) : a global, double-blind, randomised, phase 3 trial ', Lancet, vol. 393, no. 10168, pp. 229-240 . https://doi.org/10.1016/S0140-6736(18)32984-2
BACKGROUND: Based on the encouraging activity and manageable safety profile observed in a phase 1 study, the ECHELON-2 trial was initiated to compare the efficacy and safety of brentuximab vedotin, cyclophosphamide, doxorubicin, and prednisone (A+CHP
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::36b3b4862c5298b1ae704a6491430a8d
http://hdl.handle.net/20.500.11769/493757
http://hdl.handle.net/20.500.11769/493757
Autor:
William A. Wegener, Robert A. Baiocchi, Kristie A. Blum, Joseph M. Flynn, Mitch A. Phelps, Jeffrey A. Jones, Pierluigi Porcu, Don M. Benson, Lai Wei, Kami J. Maddocks, John C. Byrd, Beth A. Christian, Ming Poi, David M. Goldenberg
Publikováno v:
Br J Haematol
Summary As a result of the anti-tumour activity observed in vitro and in vivo with combined anti-CD20 and anti-CD74 antibodies, we initiated a phase I/II trial of veltuzumab and milatuzumab in patients with relapsed or refractory B-cell non-Hodgkin l
Autor:
Bradley M. Haverkos, Pierluigi Porcu, Robert A. Baiocchi, Jessica Hemminger, Henry K. Wong, Alejandro A. Gru, Anjali Mishra, Susan Geyer, Michael A. Caligiuri, Anissa Bingman, Preeti Pancholi, Aharon G. Freud
Publikováno v:
Clinical lymphoma, myelomaleukemia.
Introduction Outcomes in advanced stage (AS) cutaneous T-cell lymphomas (CTCL) are poor but with great variability. Epstein–Barr virus (EBV) is associated with a subset of non-Hodgkin lymphomas. Frequency of plasma EBV-DNA (pEBVd) detection, concor
Autor:
Jonathan W. Said, George P. Canellos, Eric D. Hsi, Raymond Lai, Amy Chadburn, Andrew D. Zelenetz, David D. Hurd, Myron S. Czuczman, Bruce D. Cheson, Wyndham H. Wilson, Pierluigi Porcu, Dan Jones, Kieron Dunleavy, Jeffrey L. Johnson, Sin-Ho Jung, S. Eric Martin
Publikováno v:
Haematologica. 97:758-765
Background A phase II trial of dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin and rituximab (DA-EPOCH-R) from the National Cancer Institute showed promising activity in untreated diffuse large B-cell lymphoma. The Can